BAT DIN 02459612
Status: Restricted Access
Holder: EMERGENT BIOSOLUTIONS CANADA INC.
Molecule: BOTULINUM ANTITOXIN SEROTYPE A
Health Canada record
| Active ingredient(s) | BOTULINUM ANTITOXIN SEROTYPE A 4500 UNIT; BOTULINUM ANTITOXIN SEROTYPE B 3300 UNIT; BOTULINUM ANTITOXIN SEROTYPE C 3000 UNIT; BOTULINUM ANTITOXIN SEROTYPE D 600 UNIT; BOTULINUM ANTITOXIN SEROTYPE E 5100 UNIT; BOTULINUM ANTITOXIN SEROTYPE F 3000 UNIT; BOTULINUM ANTITOXIN SEROTYPE G 600 UNIT |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J06AA04 BOTULINUM ANTITOXIN |
| Original market date | |
| Current status date | 25-Oct-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Emergent BioSolutions Canada Inc. — licence 3-002450, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19281 | 2017-05-09 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 18737 | 2016-12-08 | New Drug Submission (NDS) |